Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter, randomized, double-blind, placebo-controlled Phase 3 study of OV101 in Angelman syndrome
2019-002907-17Phase 3Completed
- Sponsor
- Ovid Therapeutics
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Angelman syndrome (AS) comparing OV101 with Placebo (2 arms). Primary endpoint: Primary: CGI-I-AS score at Week 12. Started Dec 2019; status: completed.
02
Drugs
gaboxadol
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on 2019-002907-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002907-17.